化合物 hCAI/II-IN-2 T61282
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
50 mg | 2480283-75-6 | ¥13,800.00 | 询底价 |
25 mg | 2480283-75-6 | ¥10,600.00 | 询底价 |
100 mg | 2480283-75-6 | ¥17,500.00 | 询底价 |
Product Introduction
Bioactivity
英文名: hCAI/II-IN-2
描述: hCAI/II-IN-2 (compound 2b) is a highly effective dual inhibitor of human carbonic anhydrase I and II (hCA I/II), with Ki values of 40.97 nM, 15.15 nM, and 61.88 nM for hCA I, hCA II, and hCA IX, respectively. With its anti-hypoxic properties, hCAI/II-IN-2 demonstrates activity against acute mountain sickness (AMS). Furthermore, this compound exhibits low cellular activity [1].
体外活性: hCAI/II-IN-2 (compound 2b) (5-200 μM, 48 hours; HEK293T cells) has no obvious toxicity at HEK293T cells [1]. Cell Cytotoxicity Assay [1] Cell Line: Embryonic kidney (HEK293T) cells Concentration: 5, 25, 50, 100 and 200 μM Incubation Time: 48 hours Result: Had no apparent cytotoxicity.
体内活性: Animal Model: Male BLAB/c mice [1] Dosage: 400 mg/kg Administration: Oral administration; 14 days. Result: Prolonged the survival time of mice by 21.7% compared with the blank control group.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
化合物 hCAI/II-IN-2 T61282信息由TargetMol中国为您提供,如您想了解更多关于化合物 hCAI/II-IN-2 T61282报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途